Vertex Pharmaceuticals Incorporated (0QZU.L)
USD 454.25
(-3.03%)
USD 454.25
(-3.03%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.14 Billion USD | 21.51% |
| 2022 | 4.23 Billion USD | 27.18% |
| 2021 | 3.33 Billion USD | 8.73% |
| 2020 | 3.06 Billion USD | 37.25% |
| 2019 | 2.23 Billion USD | 23.34% |
| 2018 | 1.81 Billion USD | 20.42% |
| 2017 | 1.5 Billion USD | -3.34% |
| 2016 | 1.55 Billion USD | 10.77% |
| 2015 | 1.4 Billion USD | 13.24% |
| 2014 | 1.24 Billion USD | 28.83% |
| 2013 | 962.63 Million USD | -36.87% |
| 2012 | 1.52 Billion USD | 23.1% |
| 2011 | 1.23 Billion USD | 1.42% |
| 2010 | 1.22 Billion USD | 42.27% |
| 2009 | 858.55 Million USD | 15.77% |
| 2008 | 741.6 Million USD | 124.6% |
| 2007 | 330.18 Million USD | -20.56% |
| 2006 | 415.64 Million USD | 34.16% |
| 2005 | 309.82 Million USD | -39.25% |
| 2004 | 510.01 Million USD | -4.05% |
| 2003 | 531.56 Million USD | 21.6% |
| 2002 | 437.13 Million USD | -2.81% |
| 2001 | 449.78 Million USD | 16.53% |
| 2000 | 385.98 Million USD | 1563.72% |
| 1999 | 23.2 Million USD | 15.42% |
| 1998 | 20.1 Million USD | 2.55% |
| 1997 | 19.6 Million USD | 54.33% |
| 1996 | 12.7 Million USD | -7.3% |
| 1995 | 13.7 Million USD | 28.04% |
| 1994 | 10.7 Million USD | -6.96% |
| 1993 | 11.5 Million USD | 61.97% |
| 1992 | 7.1 Million USD | 44.9% |
| 1991 | 4.9 Million USD | 22.5% |
| 1990 | 4 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 5.37 Billion USD | 4.29% |
| 2024 Q2 | 5.35 Billion USD | -0.25% |
| 2024 Q3 | 6.6 Billion USD | 23.37% |
| 2023 Q1 | 4.54 Billion USD | 7.17% |
| 2023 Q3 | 5.21 Billion USD | 6.85% |
| 2023 FY | 5.14 Billion USD | 21.51% |
| 2023 Q2 | 4.87 Billion USD | 7.42% |
| 2023 Q4 | 5.14 Billion USD | -1.22% |
| 2022 FY | 4.23 Billion USD | 27.18% |
| 2022 Q2 | 3.64 Billion USD | 8.95% |
| 2022 Q3 | 3.67 Billion USD | 0.77% |
| 2022 Q4 | 4.23 Billion USD | 15.27% |
| 2022 Q1 | 3.34 Billion USD | 0.5% |
| 2021 Q2 | 3.02 Billion USD | -3.49% |
| 2021 FY | 3.33 Billion USD | 8.73% |
| 2021 Q1 | 3.13 Billion USD | 2.28% |
| 2021 Q3 | 3.08 Billion USD | 2.07% |
| 2021 Q4 | 3.33 Billion USD | 7.92% |
| 2020 Q4 | 3.06 Billion USD | -3.26% |
| 2020 Q2 | 2.69 Billion USD | 10.92% |
| 2020 Q3 | 3.16 Billion USD | 17.46% |
| 2020 FY | 3.06 Billion USD | 37.25% |
| 2020 Q1 | 2.43 Billion USD | 8.88% |
| 2019 Q1 | 1.81 Billion USD | 0.5% |
| 2019 FY | 2.23 Billion USD | 23.34% |
| 2019 Q4 | 2.23 Billion USD | -1.24% |
| 2019 Q3 | 2.26 Billion USD | 15.16% |
| 2019 Q2 | 1.96 Billion USD | 7.9% |
| 2018 Q1 | 1.52 Billion USD | 1.23% |
| 2018 Q4 | 1.81 Billion USD | 7.37% |
| 2018 Q2 | 1.62 Billion USD | 6.46% |
| 2018 Q3 | 1.68 Billion USD | 4.06% |
| 2018 FY | 1.81 Billion USD | 20.42% |
| 2017 Q2 | 1.41 Billion USD | -51.87% |
| 2017 Q4 | 1.5 Billion USD | 7.79% |
| 2017 FY | 1.5 Billion USD | -3.34% |
| 2017 Q1 | 2.94 Billion USD | 89.43% |
| 2017 Q3 | 1.39 Billion USD | -1.64% |
| 2016 FY | 1.55 Billion USD | 10.77% |
| 2016 Q3 | 1.4 Billion USD | 1.89% |
| 2016 Q4 | 1.55 Billion USD | 10.62% |
| 2016 Q2 | 1.38 Billion USD | 0.61% |
| 2016 Q1 | 1.37 Billion USD | -2.33% |
| 2015 Q3 | 1.35 Billion USD | 2.37% |
| 2015 Q1 | 1.16 Billion USD | -5.79% |
| 2015 Q2 | 1.32 Billion USD | 13.49% |
| 2015 FY | 1.4 Billion USD | 13.24% |
| 2015 Q4 | 1.4 Billion USD | 3.47% |
| 2014 Q1 | 966.23 Million USD | 0.37% |
| 2014 Q3 | 1.25 Billion USD | 32.22% |
| 2014 FY | 1.24 Billion USD | 28.83% |
| 2014 Q4 | 1.24 Billion USD | -0.8% |
| 2014 Q2 | 945.55 Million USD | -2.14% |
| 2013 Q4 | 962.63 Million USD | -12.17% |
| 2013 Q3 | 1.09 Billion USD | 5.83% |
| 2013 Q2 | 1.03 Billion USD | -26.83% |
| 2013 Q1 | 1.41 Billion USD | -7.18% |
| 2013 FY | 962.63 Million USD | -36.87% |
| 2012 Q3 | 1.45 Billion USD | 6.82% |
| 2012 FY | 1.52 Billion USD | 23.1% |
| 2012 Q1 | 1.24 Billion USD | 0.12% |
| 2012 Q4 | 1.52 Billion USD | 4.87% |
| 2012 Q2 | 1.36 Billion USD | 9.75% |
| 2011 Q2 | 1.19 Billion USD | 4.52% |
| 2011 FY | 1.23 Billion USD | 1.42% |
| 2011 Q4 | 1.23 Billion USD | -8.99% |
| 2011 Q3 | 1.36 Billion USD | 13.56% |
| 2011 Q1 | 1.14 Billion USD | -6.11% |
| 2010 Q1 | 779.69 Million USD | -9.25% |
| 2010 FY | 1.22 Billion USD | 42.27% |
| 2010 Q4 | 1.22 Billion USD | -1.39% |
| 2010 Q3 | 1.23 Billion USD | 49.77% |
| 2010 Q2 | 827.06 Million USD | 6.08% |
| 2009 FY | 858.55 Million USD | 15.77% |
| 2009 Q1 | 859.03 Million USD | 15.83% |
| 2009 Q2 | 710.81 Million USD | -17.25% |
| 2009 Q3 | 964.74 Million USD | 35.72% |
| 2009 Q4 | 859.14 Million USD | -10.95% |
| 2008 Q1 | 585.25 Million USD | 77.25% |
| 2008 Q2 | 730.88 Million USD | 24.88% |
| 2008 Q3 | 717.66 Million USD | -1.81% |
| 2008 Q4 | 741.6 Million USD | 3.34% |
| 2008 FY | 741.6 Million USD | 124.6% |
| 2007 Q1 | 333.79 Million USD | -19.69% |
| 2007 Q2 | 346.48 Million USD | 3.8% |
| 2007 FY | 330.18 Million USD | -20.56% |
| 2007 Q4 | 330.18 Million USD | 2.19% |
| 2007 Q3 | 323.11 Million USD | -6.75% |
| 2006 Q1 | 291.74 Million USD | -5.83% |
| 2006 Q4 | 415.64 Million USD | 5.4% |
| 2006 Q2 | 450.48 Million USD | 54.41% |
| 2006 Q3 | 394.34 Million USD | -12.46% |
| 2006 FY | 415.64 Million USD | 34.16% |
| 2005 Q3 | 417.26 Million USD | -11.96% |
| 2005 Q4 | 309.82 Million USD | -25.75% |
| 2005 Q1 | 492.72 Million USD | -3.39% |
| 2005 FY | 309.82 Million USD | -39.25% |
| 2005 Q2 | 473.94 Million USD | -3.81% |
| 2004 Q4 | 510.01 Million USD | 1.99% |
| 2004 Q1 | 512.09 Million USD | -3.66% |
| 2004 Q2 | 513.75 Million USD | 0.33% |
| 2004 Q3 | 500.04 Million USD | -2.67% |
| 2004 FY | 510.01 Million USD | -4.05% |
| 2003 Q1 | 440.03 Million USD | 0.66% |
| 2003 FY | 531.56 Million USD | 21.6% |
| 2003 Q3 | 511.39 Million USD | 7.9% |
| 2003 Q4 | 531.56 Million USD | 3.94% |
| 2003 Q2 | 473.93 Million USD | 7.7% |
| 2002 Q3 | 422.85 Million USD | -0.22% |
| 2002 Q4 | 437.13 Million USD | 3.38% |
| 2002 Q2 | 423.79 Million USD | -0.38% |
| 2002 Q1 | 425.4 Million USD | -5.42% |
| 2002 FY | 437.13 Million USD | -2.81% |
| 2001 Q2 | 385.48 Million USD | 1.75% |
| 2001 Q3 | 446.08 Million USD | 15.72% |
| 2001 FY | 449.78 Million USD | 16.53% |
| 2001 Q4 | 449.78 Million USD | 0.83% |
| 2001 Q1 | 378.83 Million USD | -1.85% |
| 2000 Q4 | 385.98 Million USD | -29.56% |
| 2000 Q3 | 547.95 Million USD | 169.65% |
| 2000 Q2 | 203.21 Million USD | 4.11% |
| 2000 Q1 | 195.19 Million USD | 741.35% |
| 2000 FY | 385.98 Million USD | 1563.72% |
| 1999 Q1 | 20.2 Million USD | 0.5% |
| 1999 Q2 | 20 Million USD | -0.99% |
| 1999 Q3 | 18.3 Million USD | -8.5% |
| 1999 Q4 | 23.2 Million USD | 26.78% |
| 1999 FY | 23.2 Million USD | 15.42% |
| 1998 Q2 | 15.6 Million USD | 4.7% |
| 1998 Q1 | 14.9 Million USD | -23.98% |
| 1998 Q3 | 18.8 Million USD | 20.51% |
| 1998 Q4 | 20.1 Million USD | 6.91% |
| 1998 FY | 20.1 Million USD | 2.55% |
| 1997 Q4 | 19.6 Million USD | 13.95% |
| 1997 Q2 | 14.7 Million USD | 2.08% |
| 1997 Q1 | 14.4 Million USD | 13.39% |
| 1997 FY | 19.6 Million USD | 54.33% |
| 1997 Q3 | 17.2 Million USD | 17.01% |
| 1996 Q1 | 11.9 Million USD | -13.14% |
| 1996 FY | 12.7 Million USD | -7.3% |
| 1996 Q3 | 9.8 Million USD | -18.33% |
| 1996 Q4 | 12.7 Million USD | 29.59% |
| 1996 Q2 | 12 Million USD | 0.84% |
| 1995 Q2 | 13.7 Million USD | 25.69% |
| 1995 Q3 | 12.7 Million USD | -7.3% |
| 1995 Q4 | 13.7 Million USD | 7.87% |
| 1995 FY | 13.7 Million USD | 28.04% |
| 1995 Q1 | 10.9 Million USD | 1.87% |
| 1994 FY | 10.7 Million USD | -6.96% |
| 1994 Q2 | 11.3 Million USD | 20.21% |
| 1994 Q3 | 12 Million USD | 6.19% |
| 1994 Q1 | 9.4 Million USD | -18.26% |
| 1994 Q4 | 10.7 Million USD | -10.83% |
| 1993 Q4 | 11.5 Million USD | 12.75% |
| 1993 Q1 | 8.1 Million USD | 14.08% |
| 1993 Q2 | 8.4 Million USD | 3.7% |
| 1993 FY | 11.5 Million USD | 61.97% |
| 1993 Q3 | 10.2 Million USD | 21.43% |
| 1992 Q2 | 5.9 Million USD | 20.41% |
| 1992 FY | 7.1 Million USD | 44.9% |
| 1992 Q1 | 4.9 Million USD | 0.0% |
| 1992 Q3 | 6.4 Million USD | 8.47% |
| 1992 Q4 | 7.1 Million USD | 10.94% |
| 1991 FY | 4.9 Million USD | 22.5% |
| 1991 Q2 | 4.7 Million USD | 0.0% |
| 1991 Q3 | 4.6 Million USD | -2.13% |
| 1991 Q4 | 4.9 Million USD | 6.52% |
| 1990 FY | 4 Million USD | 0.0% |
| 1990 Q4 | 4 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | -3331.919% |
| Dynavax Technologies Corporation | 375.02 Million USD | -1273.192% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -956.454% |
| Perrigo Company plc | 6.04 Billion USD | 14.755% |
| Illumina, Inc. | 4.36 Billion USD | -17.952% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 90.074% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -2530.966% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 92.521% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 74.963% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -1907.884% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 27.54% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -13709.396% |
| Waters Corporation | 3.47 Billion USD | -48.131% |
| Biogen Inc. | 12.04 Billion USD | 57.247% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -6147.255% |
| Evolus, Inc. | 209.68 Million USD | -2355.946% |
| Adicet Bio, Inc. | 37.12 Million USD | -13773.384% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -7389.638% |
| bluebird bio, Inc. | 424.62 Million USD | -1112.791% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -679.34% |
| FibroGen, Inc. | 585.72 Million USD | -779.214% |
| Agilent Technologies, Inc. | 4.91 Billion USD | -4.713% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -14539.631% |
| Homology Medicines, Inc. | 118.53 Million USD | -4244.613% |
| Geron Corporation | 146.12 Million USD | -3424.195% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | -27.139% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -733.698% |
| Myriad Genetics, Inc. | 312.9 Million USD | -1545.829% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -25557.914% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -1953.284% |
| Zoetis Inc. | 9.29 Billion USD | 44.596% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -10372.182% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | -46.907% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | -172.468% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -10530.199% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | -97.812% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -1845.266% |
| Verastem, Inc. | 71.18 Million USD | -7134.389% |
| Nektar Therapeutics | 267.04 Million USD | -1828.432% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -1196.333% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -12702.168% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | -114.108% |
| OPKO Health, Inc. | 622.47 Million USD | -727.305% |
| Exelixis, Inc. | 678.44 Million USD | -659.059% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -405.18% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -4385.42% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -40986.644% |
| uniQure N.V. | 624.01 Million USD | -725.263% |
| Imunon, Inc. | 8.53 Million USD | -60269.78% |
| Blueprint Medicines Corporation | 918.64 Million USD | -460.589% |
| Insmed Incorporated | 1.66 Billion USD | -209.9% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | -212.211% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -3983.934% |
| TG Therapeutics, Inc. | 169.08 Million USD | -2945.687% |
| Incyte Corporation | 1.59 Billion USD | -223.425% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -334.362% |